Rahat Ul Ain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rahat Ul Ain has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Mahwish Faizan
University of Child Health Sciences
9 shared publications Mahwish Faizan
University of Child Health Sciences, The Children's Hospital Lahore
7 shared publicationsHuma Zafar
3 shared publicationsSaadia Anwar
Univ Child Hlth Sci, Childrens Hosp, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Lahore 54600, Punjab, Pakistan
3 shared publications- Eric Bouffet
Division of Haematology/Oncology Hospital for Sick Children Toronto Ontario Canada
2 shared publications Laeeq- Ur- Rehman
MBBS, FCPS. Department of Pediatric Neurosurgery, The Children’s Hospital, Lahore, Pakistan
2 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 11 (2)
Patterns of pain management in pediatric oncology patients: Experience from a tertiary care center in Pakistan
- 27 March 2026
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 11 (2)
Open AccessPatterns of pain management in pediatric oncology patients: Experience from a tertiary care center in Pakistan
- Open Access
- 27 February 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (4) , 816-822
When the cure becomes the curse: Radiation-induced glioma of the pons in children surviving craniopharyngioma
Background: The standard of care for pediatric craniopharyngioma (CP) is either complete surgical resection or limited debulking surgery followed by adjuvant radiotherapy (RT). Recent data favor the latter approach. Methods: We present a multi-center case series of three children with CP treated with subtotal surgery and adjuvant RT for CP who eventually developed radiation-induced glioma (RIG) of the pons. Results: The median age at diagnosis of CP was 6 years. Photon RT was administered in two patients and proton RT in one, at a median dose of 54 Gy delivered in 30 fractions. Pontine glioma was first identified on imaging after a median interval of 8 years from initial RT (range 4.5 - 9.75 years), incidentally in two asymptomatic patients during routine surveillance, and associated with symptoms of brainstem involvement in one. A biopsy was performed in two patients. One showed diffuse astrocytoma with MYCN, PDGFRA, and MDM2 amplification and a novel fusion (RBD7-FLI1), while the other case had an inconclusive histopathology. Re-irradiation (re-RT) (54 Gy/30 fractions and 30 Gy/10 fractions) was applied in two patients, and one patient received bevacizumab treatment. All three patients succumbed with a median survival of 7.5 months (range 4.0–58 months). Conclusions: Radiation-induced glioma of the pons is a rare and serious complication occurring in patients previously treated by RT for childhood CP. This secondary tumor is uniformly associated with a dramatic course regardless of the treatment modalities and resources. This highlights the need for clinical vigilance and further research to prevent it.
- 27 February 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (4) , 816-822
Open AccessWhen the cure becomes the curse: Radiation-induced glioma of the pons in children surviving craniopharyngioma
Background: The standard of care for pediatric craniopharyngioma (CP) is either complete surgical resection or limited debulking surgery followed by adjuvant radiotherapy (RT). Recent data favor the latter approach. Methods: We present a multi-center case series of three children with CP treated with subtotal surgery and adjuvant RT for CP who eventually developed radiation-induced glioma (RIG) of the pons. Results: The median age at diagnosis of CP was 6 years. Photon RT was administered in two patients and proton RT in one, at a median dose of 54 Gy delivered in 30 fractions. Pontine glioma was first identified on imaging after a median interval of 8 years from initial RT (range 4.5 - 9.75 years), incidentally in two asymptomatic patients during routine surveillance, and associated with symptoms of brainstem involvement in one. A biopsy was performed in two patients. One showed diffuse astrocytoma with MYCN, PDGFRA, and MDM2 amplification and a novel fusion (RBD7-FLI1), while the other case had an inconclusive histopathology. Re-irradiation (re-RT) (54 Gy/30 fractions and 30 Gy/10 fractions) was applied in two patients, and one patient received bevacizumab treatment. All three patients succumbed with a median survival of 7.5 months (range 4.0–58 months). Conclusions: Radiation-induced glioma of the pons is a rare and serious complication occurring in patients previously treated by RT for childhood CP. This secondary tumor is uniformly associated with a dramatic course regardless of the treatment modalities and resources. This highlights the need for clinical vigilance and further research to prevent it.
- Open Access
- 8 December 2025
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 41 (13(PINS-NN) , S105-S110
Primary central nervous system lymphoma in children: Insights from the three-year experience at the largest public-sector pediatric oncology center in Pakistan
Objective: Primary CNS lymphoma (PCNSL) in children is a rare disease, and this study aimed to document the experience of dealing with this in our geographical and resource settings. Methodology: It was an ambidirectional cohort study conducted at the Department of Pediatric Hematology/Oncology and the Department of Pediatric Neurosurgery at the University of Child Health Sciences, The Children’s Hospital Lahore, Pakistan from March 2024 to December 2024. This study included seven suspected and confirmed cases of PCNSL in children under the age of 16 years who presented to a public-sector specialized center in Pakistan over the three-year study period. Results: A total of seven cases of suspected PCNSL were included in the study. The median age at presentation was eight years, with a female-to-male ratio of 2.5:1. Most commonly presenting with a focal neurological deficit, with a median duration of symptoms of 12 weeks, and a median Lansky performance score of 50. Only 57% (04) of patients underwent surgical resection followed by adjuvant chemotherapy. Overall, 57% (03) of patients died, 29% (02) were lost to follow-up, and only 14% (01) are under treatment. Conclusion: PCNSL in children is equally rare in our part of the world, but has a dismal survival rate. Timely surgical intervention, improved supportive care, and a reduction in treatment abandonment might improve the prognosis.
- 8 December 2025
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 41 (13(PINS-NN) , S105-S110
Open AccessPrimary central nervous system lymphoma in children: Insights from the three-year experience at the largest public-sector pediatric oncology center in Pakistan
Objective: Primary CNS lymphoma (PCNSL) in children is a rare disease, and this study aimed to document the experience of dealing with this in our geographical and resource settings. Methodology: It was an ambidirectional cohort study conducted at the Department of Pediatric Hematology/Oncology and the Department of Pediatric Neurosurgery at the University of Child Health Sciences, The Children’s Hospital Lahore, Pakistan from March 2024 to December 2024. This study included seven suspected and confirmed cases of PCNSL in children under the age of 16 years who presented to a public-sector specialized center in Pakistan over the three-year study period. Results: A total of seven cases of suspected PCNSL were included in the study. The median age at presentation was eight years, with a female-to-male ratio of 2.5:1. Most commonly presenting with a focal neurological deficit, with a median duration of symptoms of 12 weeks, and a median Lansky performance score of 50. Only 57% (04) of patients underwent surgical resection followed by adjuvant chemotherapy. Overall, 57% (03) of patients died, 29% (02) were lost to follow-up, and only 14% (01) are under treatment. Conclusion: PCNSL in children is equally rare in our part of the world, but has a dismal survival rate. Timely surgical intervention, improved supportive care, and a reduction in treatment abandonment might improve the prognosis.
- Open Access
- 8 December 2025
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 41 (13(PINS-NN) , S131-S138
Primary Extraosseous Central Nervous System Ewing Sarcoma in Children: A Rare Case Series from a Major Public Neuro-Oncology Center in Pakistan
Primary extraosseous central nervous system Ewing Sarcoma (CNS-EES) in children is a rare disorder, and this study aimed to document the experience of dealing with these rare pathologies of CNS in our center. This ambidirectional descriptive case series included all consecutive cases of CNS-EES in children under the age of 16 years presenting to the The Children’s Hospital Lahore, Pakistan, from January 2023 to December 2024. During the 24-month study period, 4 out of 139 incident CNS tumor cases at our center were diagnosed as primary CNS-EES, corresponding to a proportional incidence of 2.9% (95% CI: 1.1-7.2%). The median age of presentation was 8.5 years, with equal gender distribution. Pain was the first presenting symptom, with a median symptom duration of 5.75 weeks. Half of the cases presented with a cerebral hemispheric mass and half with a spinal mass. The median event-free survival was 4.5 weeks with a survival rate of 25%. All cases were diagnosed based on a round blue cell morphology with a positive NKX2.2. Primary CNS-EES is not very infrequent in our population, with possible parietal lobe predilection and association with cancer predisposition syndrome. In resource-limited settings, NKX2.2 might serve as a fair substitute to diagnose CNS-EES.
- 8 December 2025
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 41 (13(PINS-NN) , S131-S138
Open AccessPrimary Extraosseous Central Nervous System Ewing Sarcoma in Children: A Rare Case Series from a Major Public Neuro-Oncology Center in Pakistan
Primary extraosseous central nervous system Ewing Sarcoma (CNS-EES) in children is a rare disorder, and this study aimed to document the experience of dealing with these rare pathologies of CNS in our center. This ambidirectional descriptive case series included all consecutive cases of CNS-EES in children under the age of 16 years presenting to the The Children’s Hospital Lahore, Pakistan, from January 2023 to December 2024. During the 24-month study period, 4 out of 139 incident CNS tumor cases at our center were diagnosed as primary CNS-EES, corresponding to a proportional incidence of 2.9% (95% CI: 1.1-7.2%). The median age of presentation was 8.5 years, with equal gender distribution. Pain was the first presenting symptom, with a median symptom duration of 5.75 weeks. Half of the cases presented with a cerebral hemispheric mass and half with a spinal mass. The median event-free survival was 4.5 weeks with a survival rate of 25%. All cases were diagnosed based on a round blue cell morphology with a positive NKX2.2. Primary CNS-EES is not very infrequent in our population, with possible parietal lobe predilection and association with cancer predisposition syndrome. In resource-limited settings, NKX2.2 might serve as a fair substitute to diagnose CNS-EES.
- Open Access
- 17 October 2025
- Published by Wiley
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS) or AUTOIMMUNE LYMPHOPROLIFERATIVE IMMUNODEFICIENCY (ALPID): THE ONGOING DIAGNOSTIC DILEMA: A CASE SERIES.
Background: Autoimmune Lymphoproliferative Syndrome (ALPS) is a rare inherited disorder of lymphocyte apoptosis characterized by chronic non-malignant lymphadenopathy, splenomegaly, autoimmune cytopenias, and an increased risk of lymphoma. The diagnostic hallmark is expansion of double-negative T cells (DNTs: CD3+ TCRαβ+ CD4– CD8–). Reports from low and middle-income countries remain limited, and diagnosis is often delayed or missed. We present six pediatric cases from a single center in Pakistan, highlighting their clinical and laboratory findings, management, therapeutic responses, diagnostic challenges, and outcomes. Materials & Methods : This descriptive study presents an observational case series from the pediatric Haematology Oncology department at The Children’s Hospital, University of Child Health Sciences, Lahore, Pakistan. The medical records of six patients with clinical and immunological features consistent with ALPS were reviewed. Demographic, clinical, laboratory, genetic, and treatment data were collected. Results : Six children (median age of onset 8 months) were included. Splenomegaly and autoimmune cytopenias were present in all cases, while lymphadenopathy was seen in four. All had raised double-negative T cells. Corticosteroids showed limited benefit, whereas sirolimus achieved sustained remission in most patients. One child required a splenectomy for refractory thrombocytopenia. Conclusion : ALPS should be considered in the differential diagnosis of children presenting with non-malignant lymphadenopathy and unexplained cytopenia. This case series highlights the variable clinical spectrum of ALPS in children and emphasizes the diagnostic utility of clinical and immunologic features, along with double-negative T cells, in diagnosing ALPS. Early recognition and targeted therapy are critical to improve outcomes, particularly in resource-limited settings where genetic testing is not readily available.
- 17 October 2025
- Published by Wiley
Open AccessAUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS) or AUTOIMMUNE LYMPHOPROLIFERATIVE IMMUNODEFICIENCY (ALPID): THE ONGOING DIAGNOSTIC DILEMA: A CASE SERIES.
Background: Autoimmune Lymphoproliferative Syndrome (ALPS) is a rare inherited disorder of lymphocyte apoptosis characterized by chronic non-malignant lymphadenopathy, splenomegaly, autoimmune cytopenias, and an increased risk of lymphoma. The diagnostic hallmark is expansion of double-negative T cells (DNTs: CD3+ TCRαβ+ CD4– CD8–). Reports from low and middle-income countries remain limited, and diagnosis is often delayed or missed. We present six pediatric cases from a single center in Pakistan, highlighting their clinical and laboratory findings, management, therapeutic responses, diagnostic challenges, and outcomes. Materials & Methods : This descriptive study presents an observational case series from the pediatric Haematology Oncology department at The Children’s Hospital, University of Child Health Sciences, Lahore, Pakistan. The medical records of six patients with clinical and immunological features consistent with ALPS were reviewed. Demographic, clinical, laboratory, genetic, and treatment data were collected. Results : Six children (median age of onset 8 months) were included. Splenomegaly and autoimmune cytopenias were present in all cases, while lymphadenopathy was seen in four. All had raised double-negative T cells. Corticosteroids showed limited benefit, whereas sirolimus achieved sustained remission in most patients. One child required a splenectomy for refractory thrombocytopenia. Conclusion : ALPS should be considered in the differential diagnosis of children presenting with non-malignant lymphadenopathy and unexplained cytopenia. This case series highlights the variable clinical spectrum of ALPS in children and emphasizes the diagnostic utility of clinical and immunologic features, along with double-negative T cells, in diagnosing ALPS. Early recognition and targeted therapy are critical to improve outcomes, particularly in resource-limited settings where genetic testing is not readily available.
- Open Access
- 2 May 2025
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 41 (5) , 1267-1273
Delay in diagnosis and treatment of childhood cancers in a developing country: A cross-sectional patient-based survey at country’s largest pediatric oncology center
Background & Objectives: Pediatric cancers have a huge survival gap between the high-income and the low-middle-income countries (LMICs). Despite various other causes, the advanced stage of presentation is a major contributing factor but limited data is available from developing countries in this regard. This study aimed to identify delay in treatment and factors associated with it in our setup. Methods: This was a Cross-Sectional survey conducted at the department of pediatric hematology-oncology Children Hospital Lahore using a questionnaire-based interview of parents of all newly diagnosed cases of pediatric cancers presenting to Pakistan’s largest public-sector specialized center at the Children’s Hospital Lahore, over two months, i.e. from December 1, 2023 to January 31, 2024. The data was analyzed using SPSS version 23.0. Results: A total of 119 new patients presenting to the hospital were included. The median total delay in treatment of children with cancer was 63 days which is less than comparable LMICs, but physician and healthcare system delay that makes up the major portion of the total delay is equivalent to some low-income countries. The patient delay was negligible. The statistically significant factors associated with delay were gender, age of the patient; and type of cancer. Whereas, the distance from the specialized center and the socio-economic status of the family did not contribute significantly. Conclusions: Healthcare system delay is a major contributor therefore strengthening the existing medical services, development of medical referral systems, and medical professional awareness and education can improve delays in treatment and outcomes in our setup. doi: https://doi.org/10.12669/pjms.41.5.9663 How to cite this: Rahat Ul Ain, Rahman AA, Tariq A, Faizan M. Delay in diagnosis and treatment of childhood cancers in a developing country: A cross-sectional patient-based survey at country’s largest pediatric oncology center. Pak J Med Sci. 2025;41(5):1267-1273. doi: https://doi.org/10.12669/pjms.41.5.9663 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- 2 May 2025
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 41 (5) , 1267-1273
Open AccessDelay in diagnosis and treatment of childhood cancers in a developing country: A cross-sectional patient-based survey at country’s largest pediatric oncology center
Background & Objectives: Pediatric cancers have a huge survival gap between the high-income and the low-middle-income countries (LMICs). Despite various other causes, the advanced stage of presentation is a major contributing factor but limited data is available from developing countries in this regard. This study aimed to identify delay in treatment and factors associated with it in our setup. Methods: This was a Cross-Sectional survey conducted at the department of pediatric hematology-oncology Children Hospital Lahore using a questionnaire-based interview of parents of all newly diagnosed cases of pediatric cancers presenting to Pakistan’s largest public-sector specialized center at the Children’s Hospital Lahore, over two months, i.e. from December 1, 2023 to January 31, 2024. The data was analyzed using SPSS version 23.0. Results: A total of 119 new patients presenting to the hospital were included. The median total delay in treatment of children with cancer was 63 days which is less than comparable LMICs, but physician and healthcare system delay that makes up the major portion of the total delay is equivalent to some low-income countries. The patient delay was negligible. The statistically significant factors associated with delay were gender, age of the patient; and type of cancer. Whereas, the distance from the specialized center and the socio-economic status of the family did not contribute significantly. Conclusions: Healthcare system delay is a major contributor therefore strengthening the existing medical services, development of medical referral systems, and medical professional awareness and education can improve delays in treatment and outcomes in our setup. doi: https://doi.org/10.12669/pjms.41.5.9663 How to cite this: Rahat Ul Ain, Rahman AA, Tariq A, Faizan M. Delay in diagnosis and treatment of childhood cancers in a developing country: A cross-sectional patient-based survey at country’s largest pediatric oncology center. Pak J Med Sci. 2025;41(5):1267-1273. doi: https://doi.org/10.12669/pjms.41.5.9663 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- 6 November 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (1) , e48-e51
Vanishing Bile Duct Syndrome in Pediatric Hodgkin Lymphoma: First Statistical Analysis of All Published Cases in Children and a Case Report
Hodgkin lymphoma with vanishing bile duct syndrome is a rare paraneoplastic syndrome and has never been studied in the pediatric population. The objectives of this study were to determine the clinical characteristics of this rare condition in children through a literature review, and a descriptive analysis of all published cases with the index case report. All reported cases fulfilling the inclusion criteria were found through a literature search, and analyzed in descriptive statistics. A total of 10 cases were included in the study with a median age of 9.5 years and a male-to-female ratio of 9:1. The median duration of symptoms was 5.5 weeks with 3 cases having jaundice before the symptoms of lymphoma. The median bilirubin level was 8.4 mg/dL. Seven cases received modified chemotherapy, and 5 used ursodeoxycholic acid. The survival rate was 50%. Normalization of liver functions after the lymphoma treatment was observed in 4 cases and was the only statistically significant factor (P=0.01) associated with the outcome. This is a rare entity in the pediatric population with a guarded prognosis comparable to the adult counterparts but a marked male predominance.
- 6 November 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (1) , e48-e51
Vanishing Bile Duct Syndrome in Pediatric Hodgkin Lymphoma: First Statistical Analysis of All Published Cases in Children and a Case Report
Hodgkin lymphoma with vanishing bile duct syndrome is a rare paraneoplastic syndrome and has never been studied in the pediatric population. The objectives of this study were to determine the clinical characteristics of this rare condition in children through a literature review, and a descriptive analysis of all published cases with the index case report. All reported cases fulfilling the inclusion criteria were found through a literature search, and analyzed in descriptive statistics. A total of 10 cases were included in the study with a median age of 9.5 years and a male-to-female ratio of 9:1. The median duration of symptoms was 5.5 weeks with 3 cases having jaundice before the symptoms of lymphoma. The median bilirubin level was 8.4 mg/dL. Seven cases received modified chemotherapy, and 5 used ursodeoxycholic acid. The survival rate was 50%. Normalization of liver functions after the lymphoma treatment was observed in 4 cases and was the only statistically significant factor (P=0.01) associated with the outcome. This is a rare entity in the pediatric population with a guarded prognosis comparable to the adult counterparts but a marked male predominance.
- Open Access
- 30 July 2024
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 18
Low incidence of primary immunodeficiency-associated cancers in children at a tertiary care pediatric hospital in Pakistan: a blessing in disguise or wet behind the ears?
Low incidence of primary immunodeficiency-associated cancers in children at a tertiary care pediatric hospital in Pakistan: a blessing in disguise or wet behi
- 30 July 2024
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 18
Open AccessLow incidence of primary immunodeficiency-associated cancers in children at a tertiary care pediatric hospital in Pakistan: a blessing in disguise or wet behind the ears?
Low incidence of primary immunodeficiency-associated cancers in children at a tertiary care pediatric hospital in Pakistan: a blessing in disguise or wet behi
- Open Access
- 31 January 2024
- Published by Wiley
Superior mediastinal syndrome in a child with B-cell acute lymphoblastic leukemia: A case report
Superior mediastinal syndrome secondary to an anterior mediastinal mass can be seen in acute lymphoblastic leukemia of T-cell lineage. We report a 3 years old child with B-cell ALL, who presented with superior mediastinal syndrome. The CT scan chest showed a huge anterior mediastinal mass and the peripheral blood immunophenotying showed B-cell acute lymphoblastic leukemia. High-risk remission induction chemotherapy was given and he achieved remission by the end of induction therapy, both in terms of medullary and extramedullary disease. This is the first reported case of a pediatric B-cell ALL presenting with the superior mediastinal syndrome.
- 31 January 2024
- Published by Wiley
Open AccessSuperior mediastinal syndrome in a child with B-cell acute lymphoblastic leukemia: A case report
Superior mediastinal syndrome secondary to an anterior mediastinal mass can be seen in acute lymphoblastic leukemia of T-cell lineage. We report a 3 years old child with B-cell ALL, who presented with superior mediastinal syndrome. The CT scan chest showed a huge anterior mediastinal mass and the peripheral blood immunophenotying showed B-cell acute lymphoblastic leukemia. High-risk remission induction chemotherapy was given and he achieved remission by the end of induction therapy, both in terms of medullary and extramedullary disease. This is the first reported case of a pediatric B-cell ALL presenting with the superior mediastinal syndrome.
- Open Access
- 16 December 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (24) , 3680
Evolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches
The management of medulloblastoma in children has dramatically changed over the past four decades, with the development of chemotherapy protocols aiming at improving survival and reducing long-term toxicities of high-dose craniospinal radiotherapy. While the staging and treatment of medulloblastoma were until recently based on the modified Chang’s system, recent advances in the molecular biology of medulloblastoma have revolutionized approaches in the management of this increasingly complex disease. The evolution of systemic therapies is described in this review.
- 16 December 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (24) , 3680
Open AccessEvolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches
The management of medulloblastoma in children has dramatically changed over the past four decades, with the development of chemotherapy protocols aiming at improving survival and reducing long-term toxicities of high-dose craniospinal radiotherapy. While the staging and treatment of medulloblastoma were until recently based on the modified Chang’s system, recent advances in the molecular biology of medulloblastoma have revolutionized approaches in the management of this increasingly complex disease. The evolution of systemic therapies is described in this review.